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KEYWORDS Summary  Progress  in  the  medical  treatment  of  patients  with  heart  failure  with  systolic  dys-
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function, cardiac  resynchronization  therapy,  internal  cardiac  deﬁbrillators  and  multidisciplinary
management  programmes  has  resulted  in  dramatic  improvements  in  survival  and  quality  of  life;
however, this  progress  has  led  to  an  increase  in  the  prevalence  of  advanced  heart  failure.  In
the context  of  organ  shortage  for  cardiac  transplantation,  the  technological  developments  in
left ventricular  assist  devices,  shown  in  recent  positive  clinical  studies,  provide  real  hope  for
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor antagonist; CRT, cardiac resynchronization therapy;
CMO, extracorporeal membrane oxygenation; HF, heart failure; ICD, internal cardiac deﬁbrillator; INTERMACS, Interagency Registry for
echanically Assisted Circulatory Support; LVAD, left ventricular assist device; RV, right ventricular.
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patients  with  advanced  heart  failure.  This  article  summarizes  the  most  recent  clinical  studies
concerning  left  ventricular  assist  devices  and  discusses  for  whom  and  when  a  left  ventricular
assist device  should  be  proposed.
© 2011  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé  Les  progrès  du  traitement  médicamenteux,  la  resynchronisation  cardiaque,
l’utilisation  des  déﬁbrillateurs  implantables,  l’éducation  du  patient  et  l’organisation  du  suivi
ont permis  d’améliorer  la  qualité  de  vie  et  la  survie  des  patients  insufﬁsants  cardiaques  avec
dysfonction  systolique,  mais  ces  progrès  se  sont  aussi  traduits  par  une  augmentation  de  la  pré-
valence des  patients  en  insufﬁsance  cardiaque  avancée.  Dans  le  contexte  de  pénurie  d’organes
pour la  greffe  cardiaque,  les  progrès  technologiques  des  assistances  monoventriculaires  gauches
apportent  des  résultats  cliniques  très  encourageants  et  constituent  un  réel  espoir  pour  la  prise
en charge  des  patients  insufﬁsants  cardiaques  sévères.  Cet  article  fait  le  point  sur  les  données
les plus  récentes  concernant  l’assistance  monoventriculaire  gauche  et  discute  quand  et  pour
quels patients  l’envisager.
©  2011  Elsevier  Masson  SAS.  Tous  droits  réservés.
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Background
Progress  over  the  past  20  years  in  the  medical  manage-
ment  of  patients  with  HF  with  systolic  dysfunction  has  been
accompanied  by  a  signiﬁcant  improvement  in  survival  and
quality  of  life  due  to  the  prescription  of  ACE  inhibitors,  ARBs,
beta-blockers  and  anti-aldosterones,  CRT  and  ICDs,  in  addi-
tion  to  multidisciplinary  management  programmes  based  on
education  of  the  patient  and  coordination  of  care  [1,2].
These  strategies  have  also  resulted  in  changes  in  the  clinical
proﬁle  as  well  as  an  increase  in  the  number  of  patients  with
advanced  HF.
The  prevalence  of  HF  in  Europe  is  estimated  to  be
between  2  and  3%  of  the  general  population,  with  15  million
patients  having  symptomatic  HF.  Patients  with  advanced  HF
represent  approximately  0.4%  of  the  population,  i.e.  60,000
patients.  If  we  estimate  that  around  50%  of  these  patients
have  altered  systolic  function  and  that  30−50%  are  <  75  years
of  age,  then  10—15,000  patients  should  require  a  heart
transplant,  a  total  artiﬁcial  heart,  a  biventricular  assist
device  or  a  LVAD.
Cardiologists  should  learn  to  recognize  these  patients
because  there  has  been  remarkable  progress  in  cardiac  assist
devices  over  the  past  few  years,  while  access  to  transplan-
tation  remains  very  limited.  An  LVAD  can  be  used  as  a  bridge
to  heart  transplantation,  until  possible  recovery,  or  can  be
used  long  term  or  even  permanently  (destination  therapy).
During  the  past  10  years,  1-year  survival  rates  for  destina-
tion  therapy  have  increased  from  52%  with  pulsatile  devices
[3]  to  68%  with  continuous  ﬂow  devices  [4]  and  to  94%
in  bridge-to-transplant  indications  [5].  Moreover,  the  inci-
dence  of  complications  has  dramatically  decreased  with  the
use  of  continuous  ﬂow  devices.  Their  reliability,  longevity
(>  5  years)  and  battery  autonomy  (up  to  10  h)  are  contin-
uously  improving  and  consequently  have  contributed  to  an
improvement  in  quality  of  life  [6].The  aims  of  this  article  are  to  describe  the  proﬁles  and
management  of  patients  with  advanced  HF  for  whom  an  LVAD
should  be  proposed  and  to  consider  when  an  LVAD  should  be
proposed,  on  the  basis  of  the  most  recent  clinical  studies.
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then should a heart failure (HF) patient
e  referred to an HF centre?
he  majority  of  HF  patients  with  left  ventricular  systolic  dys-
unction  are  followed  in  an  ambulatory  setting  and  should
eceive  optimal  therapy  based  on  the  use  of  recommended
edications,  CRT/ICD  devices  when  indicated  and  an  orga-
ized  care  plan  as  deﬁned  by  the  international  guidelines
7].  It  is  crucial  to  take  time  to  titrate  the  medications
p  to  the  maximal  tolerated  doses  and  to  optimize  CRT
timulation  during  the  initial  phase  and  follow-up.  At  the
dvanced  stages  of  HF,  particular  attention  should  be  paid
o  deciding  if  the  time  for  heart  transplantation  or  LVAD
mplantation  has  occurred.  The  decision  to  recommend  car-
iac  replacement  or  LVAD  implantation  remains  difﬁcult  and
oncerns  a  small  proportion  of  patients,  a large  major-
ty  of  whom  are  currently  referred  too  late.  The  paradox
s  that  these  patients,  for  whom  the  prognosis  is  worse
han  most  cancers,  are  referred  late,  while  the  level  of
ntervention  and  quality  of  management  should  at  least
qual  what  is  given  to  cancer  patients.  Hence,  patients
ith  severe  HF  should  be  directed  earlier  to  experienced
F  teams  in  order  to  discuss  therapy,  evaluate  prognosis
nd  organize  a care  plan,  allowing  elective  implantation
f  an  LVAD  if  necessary  and  pre-empting  the  evolution
f  clinical  situations.  Several  clinical  and  biological  vari-
bles  should  alert  the  primary  care  physicians  to  refer  the
atient  to  the  HF  team.  Pertinent  indicators  of  severity
an  be:  very  symptomatic  (e.g.  unable  to  climb  a  ﬂight
f  stairs  without  dyspnoea);  intolerant  to  ACE  inhibitors,
RBs  or  beta-blockers;  natraemia  <  135  mmol/L;  hospital-
zed  repeatedly  during  the  past  6  months;  and  persistent
levation  of  natriuretic  peptides.  Beyond  these  simple  indi-
ators,  HF  risk  scores  should  be  used  more  often.  The  HF
urvival  Score  [8]  and  the  Seattle  HF  Score  [9]  seem  to
e  relevant  in  these  patients,  even  if  they  can  underevalu-
te  prognosis  in  the  most  severe  patients;  their  routine  use
s  not  frequent  in  Europe  but  the  severity  of  the  patients
hould  justify  broader  utilization  of  these  scores  to  facili-
ate  the  best  treatment  strategies.  Earlier  referral  has  to  be
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referred  to  improve  patient  selection  for  LVAD  implantation
r  heart  transplantation.
The  HF  team  will  ensure  that  all  conventional  medical
trategies  have  been  optimally  implemented  and  will  accu-
ately  evaluate  right  heart  function  as  well  as  other  factors
hat  can  inﬂuence  the  therapeutic  decision  (see  below).
ased  on  this  evaluation,  a  strategy  of  management  and
utpatient  follow-up  will  be  proposed  in  collaboration  with
he  cardiologist  and  general  practitioner.  This  period  of  time
rovides  a  good  opportunity  to  implement  patient  education
nd  give  information  about  LVADs  and  heart  transplanta-
ion.  Heart  transplantation  currently  offers  the  best  quality
f  life,  autonomy  and  chance  of  socioprofessional  reinte-
ration  and  the  longest  survival.  However,  the  shortage  of
rgan  donors  dramatically  limits  the  probability  of  trans-
lantation  in  ambulatory  waiting  patients  and  emergency
ransplantation  is  given  priority  in  industrialized  countries.
n  this  context,  during  consultations  where  heart  transplan-
ation  is  discussed,  the  possible  requirement  for  a  period  of
ridge  assistance  until  transplantation  should  be  systemati-
ally  mentioned.
or which patients should a left
entricular assist device be proposed?
atients with chronic heart failure
s  recommended  by  the  European  Society  of  Cardiology,
n  LVAD  may  be  considered  as  a  destination  therapy  to
educe  mortality  in  patients  in  New  York  Heart  Association
lass  3B  to  4,  who  remain  symptomatic  despite  optimiza-
ion  of  the  recommended  HF  medications  (Fig.  1)  [10].
s  described  by  the  European  working  group  on  advanced
eart  failure  these  patients  complain  of  major  limitations
n  their  daily  life,  with  dyspnoea  and  fatigue  present  at
est  or  during  minimum  effort,  which  conﬁnes  them  to  bed
r  at  home.  For  ambulatory  patients,  excursions  outside
re  feared  and  rare,  and  walking  is  limited.  These  patients
igure 1. Clinical course of heart failure. ACC: American College
f Cardiology; AHA: American Heart Association; BiVAD: biventric-
lar assist device; LVAD: left ventricular assist device; NYHA: New
ork Heart Association.
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ave  repeated  episodes  of  salt  and  water  retention  or  low
ardiac  output  episodes  and  are  often  rehospitalized,  with
ore  than  one  hospitalization  during  the  previous  6  months.
ll  these  signs  appear  despite  optimization  of  (or  attempts
o  optimize)  their  medications  [11]. These  patients  do  not
espond  to  cardiac  resynchronization  therapy  or  respond
nly  transiently  and  inverse  left  ventricular  remodeling  is
ot  observed.  Above  all,  drug  titration  is  often  impossible
nd  at  the  most  advanced  stages,  drug  treatments  (ACE
nhibitors,  ARBs,  beta-blockers,  antialdosterones)  have  to
e  decreased  due  to  hypotension,  renal  insufﬁciency  and
rofound  weakness.  At  this  stage  of  advanced  HF,  the  main
bjective  becomes  optimization  of  volaemia  and  high  doses
nd  combinations  of  diuretics  have  to  be  used.  The  classi-
cation  of  the  INTERMACS  registry  proposes  seven  clinical
cenarios  that  allow  better  deﬁnition  of  the  functional  limi-
ations  and  degree  of  severity  of  patients  with  advanced  HF
Table  1)  [12]. Although  this  classiﬁcation  does  not  take  into
ccount  the  arrhythmic  risk,  it  is  extremely  useful  in  daily
linical  practice  for  the  management  of  patients  and  for
aking  decisions  regarding  therapeutic  strategies.  Commu-
ity  cardiologists  should  know  this  classiﬁcation  since  it  also
as  a  prognostic  value  [13]. These  patients  have  a  profound
lteration  of  left  ventricular  ejection  fraction  (<  25%).  The
lteration  of  systolic  function  should  not  be  underestimated,
nd  higher  values  may  be  found  in  cases  of  signiﬁcant  mitral
nsufﬁciency.  Echocardiography  shows  marked  anomalies  in
he  mitral  proﬁle  and  an  increase  in  ﬁlling  pressure  concor-
ant  with  the  level  of  natriuretic  peptides,  which  remain
ncreased  between  congestive  episodes  [11]. An  increase  in
entral  venous  pressure  despite  haemodynamic  optimization
ndicates  an  alteration  of  RV  function.  It  is  crucial  to  perform
 comprehensive  evaluation  of  RV  function  and  to  identify
V  dysfunction  because  this  is  a  determining  prognostic  fac-
or.  During  follow-up  of  ambulatory  HF  patients,  an  increase
n  pulmonary  pressure  and/or  pulmonary  resistance  should
irect  the  patient  to  a  HF  reference  centre  because  this
ndicates  advanced  disease  and  an  increased  risk  of  RV  dys-
unction.  RV  dysfunction  is  one  of  the  main  determinants
f  operative  risk  and  may  preclude  the  possibility  of  LVAD
mplantation.  The  patient’s  age  is  not  a  formal  contraindi-
ation  and  depending  on  the  general  state  of  the  patient  and
he  presence  of  comorbidities,  implantation  of  mechanical
ssistance  may  be  proposed  in  patients  >  65  years  of  age  [14].
atients with acute heart failure
he  sickest  patients  experiencing  profound  cardiogenic
hock  are  contraindicated  for  long-term  circulatory  support
nd  should  be  ﬁrst  stabilized  with  peripheral  transitory  cir-
ulatory  systems,  such  as  ECMO  or  others,  but  this  topic
ill  not  be  discussed  in  this  article.  Hence,  patients  with
ultiple  organ  failure  are  not  an  indication  for  an  LVAD,
xcept  for  an  extremely  limited  number  of  patients  in  whom
 bridging  strategy  may  be  implemented  until  the  decision
s  made.  Only  teams  with  wide  experience  in  this  type  of
anagement  should  take  this  decision,  and  patients  with
ardiogenic  shock  have  to  be  transferred  as  soon  as  possible
o  experienced  centres.  Patients  who  are  type  1  or  2  in  the
NTERMACS  classiﬁcation  are  currently  the  main  indication.
he  need  to  increase  doses  of  inotropes,  vasopressors  and
he  development  of  signs  of  multiple  organ  failure  are  deter-
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Table  1  Interagency  Registry  for  Mechanically  Assisted  Circulatory  Support  (INTERMACS)  classiﬁcation.
Classiﬁcation  Description  Time  frame  for
deﬁnitive  intervention
1  Patient  with  life-threatening  hypotension  despite  rapidly  escalating
inotropic  support,  critical  organ  hypoperfusion  with  increasing  lactate
levels  and/or  systemic  acidosis.  ‘‘Crash  and  burn’’
Needed  within  hours
2 Patient  with  declining  function  despite  intravenous  inotropic  support,
may  be  manifested  by  worsening  renal  function,  nutritional  depletion,
inability  to  restore  volume  balance.  ‘‘Sliding  on  inotropes’’
Needed  within  a  few
days
3  Patient  with  stable  blood  pressure,  organ  function,  nutrition  and
symptoms  on  continuous  intravenous  inotropic  support,  but  demonstrating
repeated  failure  to  wean  owing  to  recurrent  symptomatic  hypotension  or
renal  dysfunction.  ‘‘Dependent  stability’’
Elective  over  a  few
weeks
4 Patient  can  be  stabilized  close  to  normal  volume  status  but  experiences
frequent  relapses  into  ﬂuid  retention,  generally  with  high  diuretic  doses.
Symptoms  are  recurrent  rather  than  refractory.  More  intensive
management  strategies  should  be  considered,  which  in  some  cases  reveal
poor  compliance.  ‘‘Frequent  ﬂyer’’
Elective  over  weeks  to
months  as  long  as
treatment  of  episodes
restores  stable
baseline,  including
nutrition
5 Patient  is  living  predominantly  within  the  house,  performing  activities  of
daily  living  and  walking  from  room  to  room  with  some  difﬁculty.  Patient  is
comfortable  at  rest  without  congestive  symptoms  but  may  have
underlying  refractory  elevated  volume  status,  often  with  renal
dysfunction.  ‘‘Housebound’’
Variable, depends  upon
nutrition,  organ
function,  and  activity
6  Patient  without  evidence  of  ﬂuid  overload  is  comfortable  at  rest  and  with
activities  of  daily  living  and  minor  activities  outside  the  home,  but
fatigues  after  the  ﬁrst  minutes  of  any  meaningful  activity.  ‘‘Walking
wounded’’
Variable,  depends  upon
nutrition,  organ
function,  and  activity
7  A  placeholder  for  future  speciﬁcation,  patients  without  recent  unstable
ﬂuid  balance,  living  comfortably  with  meaningful  activity  limited  to  mild
exertion
Transplantation  or
circulatory  support  not
currently  indicated
Reprinted from [11] with permission from Elsevier.
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bmining  factors  that  should  make  clinicians  consider  urgent
LVAD  implantation  [15]. Low  SvO2 or  high  lactate  levels  are
useful  criteria  for  assessing  oxygen  dependence  and  multi-
ple  organ  failure  at  an  early  stage.  Under  these  conditions,
this  usually  takes  place  as  rescue  therapy  in  a  patient  who  is
a  candidate  for  transplantation,  while  in  the  case  of  destina-
tion  therapy,  LVADs  should  be  reserved  for  stabilized  patients
only.  Level  3  patients  are  dependent  on  intravenous  perfu-
sion  of  positive  inotropes.  Multiple  attempts  to  withdraw
inotropes  should  be  avoided  in  favour  of  LVAD  implantation
in  the  current  context  of  a  shortage  of  grafts  [15]. In  France,
the  national  regulations  on  the  distribution  of  grafts  deter-
mined  by  the  Biomedicine  Agency  restricts  the  possibility  of
a  patient  being  given  national  priority  to  two  48-hour  peri-
ods  and  the  shortage  of  grafts  should  encourage  clinicians
to  use  LVADs  (Fig.  2).
Main contraindications
A  preassistance  assessment  is  necessary  and  is  similar  to  the
pretransplantation  assessment,  with  general  examinations
to  look  for  temporary  or  permanent  contraindications.  A
number  of  contraindications  should  rule  out  an  LVAD:  severe
chronic  respiratory  failure;  severe  liver  failure;  major
c
a
C
wroblem  in  the  clotting  test;  uncontrolled  haemorrhage;
ncontrolled  septic  or  inﬂammatory  syndrome;  multiple
rgan  failure;  recent  cerebrovascular  accident;  psychiatric
isorder  compromising  compliance  with  treatment;  and  life-
xpectancy  <  2  years.  A  number  of  comorbidities  may  be
olerated  and  individually  should  not  contraindicate  an  LVAD
n  a  case-by-case  basis.  Reversible  and  disproportionate
ostcapillary  pulmonary  arterial  hypertension  is  not  a  con-
raindication  if  RV  function  is  preserved  or  only  altered
lightly.  Moderate  renal  failure  in  relation  to  an  acute  or
hronic  cardiorenal  syndrome  should  recover  in  line  with
he  improvement  in  peripheral  blood  ﬂow  [16]. A  history
f  cancer  considered  as  cured  and  a  slowly  evolving  cancer
hat  is  well  controlled  by  speciﬁc  treatment  are  not  con-
raindications  for  an  LVAD.  A  history  of  thoracotomy  does
ot  contraindicate  LVAD  surgery  but  may  affect  the  route
f  access  for  the  intervention  and  the  model  of  assistance.
he  presence  of  a  mechanical  mitral  valve  is  associated
ith  a  high  risk  of  embolism  and  a  replacement  by  a
ioprothesis  should  be  discussed.  Aortic  regurgitation  is  a
ontraindication  if  it  is  not  cured  during  the  procedure.  An
pical  thrombosis  has  to  be  tracked  before  implantation.
linicians  should  be  particularly  vigilant  for  denutrition,
hich  should  be  corrected  before  surgery.  The  presence  of
118  J.-N.  Trochu  et  al.
Figure 2. For which heart failure patients could left ventricular assist device be proposed? ACE-I: angiotensin-converting enzyme inhibitor;
BB: beta-blocker; CRT: cardiac resynchronization therapy; ICD: internal cardiac deﬁbrillator; LVEF: left ventricular ejection fraction; MR:
m entri
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ell-controlled  and  uncomplicated  diabetes  is  not  a  con-
raindication.  However,  a  combination  of  several  relative
ontraindications  will  lead  to  a  deﬁnitive  contraindication;
or  example,  age,  poorly  controlled  diabetes,  renal  failure
nd  arteriopathy  together  in  the  same  patient  will  strongly
ffect  the  operative  risk  and  should  contraindicate  the
atient.
onﬁrmation of the cardiological
ndication
ssessment of  right ventricular function
ne  priority  of  the  cardiovascular  assessment  is  a  thor-
ugh  evaluation  of  right  heart  function  [17]. Evaluation
f  RV  function  should  always  take  into  account  pulmonary
ressure  values  and  vice  versa.  Slightly  raised  or  normal
ulmonary  pressure  in  the  presence  of  indicators  of  RV
ystolic  dysfunction  does  not  rule  out  the  presence  of
ncreased  pulmonary  resistance  and  should  raise  the  pos-
ibility  of  postoperative  right  HF.  RV  dysfunction  is  one
f  the  complications  that  signiﬁcantly  increases  morbid-
ty  and  mortality  after  an  LVAD  implantation  [18]. The
requency  of  this  complication  ranges  from  20—30%  depend-
ng  on  the  severity  of  preoperative  dysfunction  and  the
ype  of  assistance.  However,  the  frequency  has  decreased
ince  the  use  of  continuous  ﬂow  LVADs  [4]  and  a  transient
V  assist  device  is  not  always  necessary.  Before  elective
p
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urgery,  RV  dysfunction  can  be  decreased  by  optimization  of
olaemia  and  haemodynamics  by  systematic  preoperative
anagement  [19]. At  an  advanced  stage  of  HF,  evaluation
f  the  risk  of  postoperative  right  decompensation  is  com-
lex  and  several  scores  have  been  described  and  appear
ertinent  for  determining  the  assistance  strategy  and  the
eed  for  biventricular  assistance.  These  scores  take  into
ccount  a  number  of  clinical,  haemodynamic,  echocar-
iographic  and  biological  factors:  alteration  of  RV  stroke
ork  index  (<  300  mmHg/mL/m2);  central  venous  pres-
ure  >  16—18  mmHg;  mean  pulmonary  pressure  <  25  mmHg
nd  low  diastolic  pressure  <  15  mmHg  under  perfusion  of
ositive  inotropes;  increase  in  pulmonary  vascular  resis-
ance;  echocardiographic  signs  of  altered  RV  systolic
unction;  decreased  systolic  arterial  pressure  ≤  96  mmHg;
ilirubin  ≥  2.0  mg/dL;  creatinine  >  1.9—2.3  mg/dL;  aspar-
ate  aminotransferase  ≥  80  IU/L;  ascites;  multiorgan  failure
oliguria,  increase  in  international  normalized  ratio);  or
eed  for  vasopressors  [20—24]. Invasive  measurement  of
ulmonary  pressure  and  its  reversibility  is  systematic  and
ust  be  carried  out  by  the  HF  centre  doing  the  implan-
ation;  it  is  also  important  that  this  evaluation  is  carried
ut  before  the  initiation  of  ECMO.  The  pharmacological  test
ses  a  combination  of  positive  inotropes,  intravenous  and
nhaled  (nitric  oxide)  pulmonary  vasodilators  and  diuret-
cs  in  order  to  optimize  central  venous  pressure,  capillary
ressure,  transpulmonary  gradient  and  systemic  and  pul-
onary  vascular  resistance.  This  optimization  enables  the
ccurate  evaluation  of  RV  systolic  function.  Kormos  et  al.
19]  showed  that  84%  of  patients  who  did  not  have  RV
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Figure 3. Left ventricular assist device (LVAD) or biventricular
assist device (BiVAD) strategies according to clinical proﬁles. BTR:
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dysfunction  at  the  time  of  implantation  of  an  LVAD  had
systolic  pulmonary  pressure  >  52  mmHg,  while  only  5%  of
patients  with  RV  dysfunction  had  raised  pulmonary  pressure.
Several  studies  have  also  highlighted  the  value  of  measur-
ing  the  contractile  reserve  at  the  time  of  pharmacological
testing;  at  the  advanced  stage  of  HF  and  despite  the  pres-
ence  of  both  pulmonary  arterial  hypertension  and  RV  systolic
dysfunction,  perfusion  of  dobutamine  may  reveal  the  exis-
tence  of  a  contractile  reserve  in  the  form  of  an  increase
in  pulmonary  pressure  and  tricuspid  annular  plane  systolic
excursion  [25].
Operative risk evaluation
Scores  for  operative  risk  speciﬁc  to  LVAD  implantation  have
been  validated.  These  take  into  account  general  state,
nutritional  status,  renal  and  hepatic  dysfunction,  haemor-
rhagic  risk,  right  cardiac  dysfunction  and  use  (or  not)  of
vasodilators.  Their  role  is  to  help  medicosurgical  teams
to  decide  the  indication,  stratify  patients  with  different
degrees  of  risk  and  evaluate  the  change  in  risk  after  thera-
peutic  optimization  [15,26].
Conﬁrmation of the indication
The  general  evaluation  of  the  patient  should  attempt  to
eliminate  a  permanent  or  relative  contraindication.  In  par-
ticular,  neurological  investigations  (brain  scan  or  magnetic
resonance  imaging)  should  evaluate  the  presence  of  a
preoperative  stroke.  Intestinal  investigations  (oesophogas-
troduodenal  ﬁbroscopy,  colon  scan)  should  look  for  potential
causes  of  digestive  bleeding,  as  an  increased  risk  in
patients  with  continuous  ﬂow  circulatory  assistance  has
been  described.  Urological  and  gynecological  investigations
are  also  carried  out  systematically.  All  concurrent  ailments
and  infections  should  be  treated  before  the  intervention.
Psychiatric  and  psychological  consultations  should  be
carried  out  because  mood  disorders  are  often  difﬁcult  to
diagnose  at  this  stage  and  their  treatment  is  essential  in  the
context  of  the  long-term  follow-up  of  LVAD  patients.  Psy-
chological  follow-up  should  take  place  systematically.  It  is
crucial  to  meet  with  the  patient’s  family  because,  despite
recent  progress,  LVAD  patients  depend  on  their  relatives,
who  should  be  capable  of  taking  over  from  them  in  managing
the  electrical  supply.  Assessment  of  the  patient’s  relatives  is
therefore  important  before  assistance  and  their  education
is  required.  A  meeting  with  an  assisted  patient  should  be
proposed  systematically.
Strategy and follow-up of advanced heart
failure patients
Several  clinical  situations  may  present  (Fig.  3).  Most  often,
the  haemodynamic  state  is  unstable,  the  patient  is  depen-
dent  on  inotropes,  the  period  of  national  priority  on  the
waiting  list  has  not  resulted  in  a  graft  and  the  indication
for  an  implant  has  been  conﬁrmed;  this  will  be  orga-
nized  within  several  days,  with  (or  without)  the  need  for  a
period  of  optimization  before  surgery  (treatment  of  conges-
tion,  denutrition,  pulmonary  infection,  etc.).  The  implant  is
n
i
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wridge to recovery; DT: destination therapy; HTx: heart transplan-
ation; RVAD: right ventricular assist device; RVF: right ventricular
unction.
onsidered  as  a bridge  until  transplantation  or  a destination
herapy.
The  second  most  common  situation  is  that  of  a  patient
ith  class  IV  non-congestive  HF,  or  class  III  with  recurrent
pisodes  of  congestion.  In  these  highly  unstable  patients,
linicians  should  consider  a  decision  within  a  few  weeks,
llowing  a  period  of  reﬂection  for  the  patient.  This  is  a  crit-
cal  period  during  which  deterioration  of  right  heart  function
ay  occur  rapidly  and  close  clinical  surveillance  is  manda-
ory.  The  follow-up  of  patients  with  severe  HF  for  whom  an
VAD  is  being  considered  but  has  not  yet  been  decided  upon
ncludes  monthly  visits  to  the  general  practitioner  and/or
ardiologist  as  well  as  clinical  and  biological  reassessment  at
east  every  3  months  within  the  reference  centre.  Echocar-
iographic  monitoring  should  be  carried  out  every  3  months
o  detect  possible  recovery  and  signs  of  inverse  remodeling;
t  should  systematically  evaluate  pulmonary  pressure  and
he  development  of  RV  dysfunction.
In  a  number  of  cases,  the  indication  for  an  LVAD  is  not  con-
rmed  due  to  a  permanent  contraindication  or  if  it  appears
o  be  too  early  or  if  there  is  the  possibility  of  optimization  of
edical  treatment.  In  this  situation,  alternating  follow-up
y  the  cardiologist  and  an  HF  centre  should  be  organized  on
 three-monthly  cycle.
The  observation  of  biventricular  failure  will  direct  the
atient  towards  heart  transplantation  or,  in  the  case  of  insta-
ility,  towards  biventricular  bridge  assistance  or  artiﬁcial
eart  until  transplantation.
urgery for left ventricular assist device
mplantation
 short  period  of  hospitalization  prior  to  surgery  is  favoured.
urgery  for  implantation  of  an  LVAD  device  is  currently
o  more  serious  than  that  required  for  a  transplant,  and
f  implantation  is  carried  out  correctly,  good  functioning
f  the  pump  is  certain,  which  is  not  always  the  case
ith  a  heart  transplant.  The  route  of  approach  may  be  a
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ertical  median  sternotomy  or  a  thoracotomy,  depending  on
he  type  of  assistance.  Implantation  of  an  LVAD  is  carried
ut  with  a  beating  heart,  with  or  without  extracorporeal
irculation/ECMO  assistance.  In  all  cases,  the  drainage  can-
ula  is  positioned  at  the  apex  of  the  left  ventricle  and
he  ejection  tube  on  the  aorta  (ascending  or  descending
epending  on  the  approach).  Miniaturization  of  the  pumps
llows  them  to  be  implanted  directly  in  the  pericardial
avity  and  the  possibility  of  not  using  extracorporeal  cir-
ulation  or  only  an  ECMO  system  greatly  reduces  the  risk
f  haemorrhagic  complications.  Tunellization  of  the  drive
ine  connecting  the  pump  to  its  external  controller  should
e  carried  out  carefully  in  order  to  avoid  bleeding,  which
s  a  source  of  secondary  infection.  Before  closure  of  the
horax,  it  is  important  to  take  precautions  to  avoid  the
ormation  of  intrapericardic  adherences  in  order  to  facili-
ate  reoperation;  for  this,  membranes  (resorbable  or  not)
re  arranged  around  the  heart  and  the  pump.  Peroperative
ransoesophageal  echocardiography  is  necessary  to  assess
he  absence  of  air  in  the  cardiac  cavity,  the  opening  of  the
ight-left  shunt,  good  positioning  of  the  apical  cannula,  the
agnitude  of  left  ventricular  ﬂow  and  RV  function.  Several
actors  favour  the  protection  of  RV  function:  implantation
ith  a  beating  heart,  limited  left  assistance  ﬂow  in  the  ﬁrst
ew  days  and  decreases  in  pulmonary  arterial  pressure.  The
re-emptive  temporary  use  of  right  assistance  should  be  pro-
osed  when  necessary  or  without  delay  or  by  default  if  RV
ailure  develops.  If  implantation  is  carried  out  under  periph-
ral  ECMO,  this  should  be  left  in  place  during  closure  of
he  thorax  and  even  longer  if  necessary,  so  that  the  right
entricle  is  not  charged  too  quickly.  Postoperatively,  partic-
lar  attention  should  be  paid  to  haemostasis,  to  the  quality
f  left  ventricular  ﬂow  and  to  RV  function.  Regular  mea-
urement  of  ﬂow  by  echocardiography  or  SvO2 Swan-Ganz
atheter  may  be  necessary  as  ﬂow  estimated  by  the  pumps  is
ot  reliable  in  all  situations.  Special  care  should  also  be  paid
o  immobilization  of  the  percutaneous  driveline  and  to  the
ound  dressing  to  prevent  infection.  Experienced  nurses  and
he  skills  of  the  intensive  care  unit  are  the  keys  to  success.
rganization of ambulatory follow-up of
eft  ventricular assist device
he  postoperative  period  of  hospitalization  is  used  to  edu-
ate  the  patient  and  his/her  entourage  concerning  the
echnical  aspects  of  assistance,  wound  care  of  the  exit  site
f  the  percutaneous  drive  line,  the  basic  hygiene  precau-
ions  required  and  the  measures  to  prevent  infection.  Before
eaving  the  hospital,  the  patient  should  have  mastered
echarging  and  replacing  of  the  the  batteries,  knowledge  of
he  autonomy  of  the  batteries,  use  of  the  controller  and  test
rocedures,  recognition  of  warning  signs/main  alarms  and
anagement  of  unusual  situations.  At  least  one  person  in  the
atient’s  entourage  should  be  trained  to  change  the  battery
efore  authorization  is  given  for  the  patient  to  leave  the  HF
nit.  The  hygiene  precautions  regarding  the  wound  are  cru-
ial  and  the  reference  centre  should  also  train  the  nurse  who
s  responsible  for  caring  for  the  patient  at  home.  However,
ome  centres  train  patients  to  change  the  wound  dressing
hemselves.  Education  regarding  medical  treatment  is  also
d
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iven  in  parallel—particularly  the  management  of  anticoagu-
ants.  The  level  of  anticoagulation  differs  slightly  depending
n  the  system  but  the  target  international  normalized  ratio
s  generally  around  2;  antiplatelet  agents  are  given  fre-
uently  but  not  systematically.  It  is  necessary  to  organize  a
tay  in  rehabilitation  before  the  patient  returns  home,  dur-
ng  which  they  undertake  a  programme  of  physiotherapy  in
rder  to  consolidate  muscular  reconditioning  and  train  them
o  perform  regularly  physical  activities.  This  period  enables
he  reinforcement  of  education.  Before  home  discharge,  a
eeting  that  includes  the  general  practitioner,  local  nurse,
oordinating  nurse  from  the  HF  centre  and  the  LVAD  coor-
inator  and  technician  can  be  organized.  The  HF  centre  is
rimarily  responsible  for  the  follow-up  and  the  delivery  of
nformation  to  the  health  care  providers  and  local  ambu-
ance  service  about  the  speciﬁc  management  of  the  LVAD
atient.  The  quality  of  the  organization  of  the  ambulatory
anagement  is  crucial  and  the  reference  centre  should  be
rganized  to  respond  to  care  providers  and  patients’  calls  or
eed  for  assistance  on  a  24-hour  basis,  365  days  per  year.
Ambulatory  follow-up  will  include  an  initial  monthly
ollow-up  at  the  HF  centre,  followed  by  a  visit  every
—3  months.  The  ventricular  assist  device  coordinator,  ref-
rent  cardiologists  and  surgeons  are  involved  in  the  clinical
nd  echocardiographic  monitoring,  wound  control,  techni-
al  check-up  and  CRT/ICD  monitoring.  Transient  opening
nd  remodeling  of  the  aortic  valve  should  be  monitored,
s  well  as  RV  function  and  tricuspid  insufﬁciency.  Medical
reatment  (ACE  inhibitors,  AA2  antagonists,  beta-blockers,
ineral  receptor  antagonists,  diuretics)  is  maintained  but
rterial  pressure  should  not  be  decreased  too  markedly  and
ean  systemic  arterial  pressure  should  stay  above  80  mmHg
o  insure  sufﬁcient  pump  ﬂow.  Irrespective  of  the  aetiol-
gy,  2—4%  of  patients  may  recover  and  this  should  therefore
e  monitored  during  follow-up.  Inverse  remodeling  may  be
rogressive.  Recovery  of  functional  capacities  can  be  stud-
ed  using  the  exercise  test  VO2 (at  months  3,  6  and  12
f  follow-up).  Ventricular  arrhythmias  should  be  detected
ystematically  and  treated.  Psychological  follow-up  is  very
mportant  and  interviews  should  be  proposed  systematically
o  the  patient.
Regular  meetings  should  also  be  held  with  the  patient’s
ntourage.  Travel  is  allowed  as  well  as  driving  a  car.  Air
ravel  is  possible  but  the  airline  company  should  be  warned
n  advance  of  the  constraints  of  batteries  and  the  possi-
le  need  to  use  an  electrical  supply  during  the  ﬂight.  A
eference  centre  close  to  the  travel  destination  should  be
ontacted  in  advance  and  the  location  conveyed  to  the
atients  and  their  family.
onclusion
ramatic  improvements  in  survival  and  quality  of  life  have
een  observed  during  the  past  5  years  in  LVAD  patients  in
elation  to  technical  progress.  LVADs  are  now  part  of  the
reatment  of  HF  patients  as  bridges  to  transplantation  or  as
estination  therapy.  Clinical  cardiologists  have  to  be  aware
f  this  important  evolution  in  the  context  of  increasing  num-
ers  of  advanced  HF  patients.  The  cardiological  community
hould  master  recognition  of  the  severity  of  advanced  HF
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patients  as  patient  selection  and  timing  of  implantation  are
the  keys  to  success.
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